GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » 3-Year RORE %

NVN Liquidation (NVN Liquidation) 3-Year RORE % : 0.00% (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. NVN Liquidation's 3-Year RORE % for the quarter that ended in Mar. 2023 was 0.00%.

The industry rank for NVN Liquidation's 3-Year RORE % or its related term are showing as below:

NOVNQ's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -5.96
* Ranked among companies with meaningful 3-Year RORE % only.

NVN Liquidation 3-Year RORE % Historical Data

The historical data trend for NVN Liquidation's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NVN Liquidation 3-Year RORE % Chart

NVN Liquidation Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only -71.15 -24.95 -29.22 -57.71 -30.66

NVN Liquidation Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.53 -53.37 -41.18 -30.66 -20.56

Competitive Comparison of NVN Liquidation's 3-Year RORE %

For the Biotechnology subindustry, NVN Liquidation's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NVN Liquidation's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NVN Liquidation's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where NVN Liquidation's 3-Year RORE % falls into.



NVN Liquidation 3-Year RORE % Calculation

NVN Liquidation's 3-Year RORE % for the quarter that ended in Mar. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -1.32--2.49 )/( -5.69-0 )
=1.17/-5.69
=-20.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2023 and 3-year before.


NVN Liquidation  (OTCPK:NOVNQ) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


NVN Liquidation 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of NVN Liquidation's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NVN Liquidation (NVN Liquidation) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 64, Pittsboro, NC, USA, 27312
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman director 9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour director C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay officer: VP, Finance & Corp. Controller C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John officer: EVP, Chief Operating Officer C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky director TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin director C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram director 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer director 7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak officer: Chief Accounting Officer C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513